Canopy Growth Q1 Revenue Jumps 13%, Loss Narrows 68% on Broad-Based Strength
CGC is trading near its 52-week low of $0.844 (14% above the low) on light trading volume (0.3× avg).
Summary
Canopy Growth posted Q1 FY2027 revenue of C$81.2M, up 13% year-over-year, with growth across all segments: Canada medical cannabis (+22%), adult-use (+10%), international (+10%), and Storz & Bickel (+6%). Adjusted gross margin expanded to 31% from 25%, and adjusted EBITDA loss narrowed 59% to C$3.2M. Net loss improved 68%. The results reflect early benefits from the MTL Cannabis acquisition, driving flower supply and revenue, though free cash outflow widened to C$25.7M on working capital timing. This follows the June 2026 restatement and proxy filing for a reverse stock split to maintain Nasdaq listing. The improving operational trends and narrowing losses signal progress toward profitability, but the looming reverse split and Acreage default remain overhangs.
At the time of this announcement, CGC was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $415.3M. The 52-week trading range was $0.84 to $2.38. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.